Navigation Links
arGEN-X Granted Broad Patent Covering its Unique SIMPLE Antibody(TM) Platform
Date:7/8/2010

ompanies through selective strategic partnerships and by developing its own portfolio of exciting therapeutic antibody candidates.

The power of the SIMPLE Antibody(TM) platform is enabling the Company to rapidly build its own pipeline. arGEN-X' lead product, ARGX-109, a fully human mAb targeting autoimmune, inflammation and oncology indications, has already entered preclinical development in less than 12 months from start of the discovery process. ARGX-109, which targets the cytokine IL-6, has already shown very high potencies in a range of in vivo studies. arGEN-X currently has a further three therapeutic antibody candidates in its own development pipeline.

Note to Editors

About arGEN-X - http://www.arGEN-X.com

arGEN-X is a preclinical stage biopharmaceutical company with a broadly applicable, proprietary SIMPLE Antibody(TM) platform. The platform allows arGEN-X to create an unparalleled diversity of in vivo generated antibody leads against a broad range of human disease targets. This superior choice of ultra-high affinity and highly potent leads, having best-in-class human homology, allows for more stringent lead selection criteria, thereby increasing the probability of success later in the drug development path. The Company has validated its platform on four human disease targets to date. The Company's first patent was granted by the UK Patent and Trademark Office in July 2010. arGEN-X is globally prosecuting additional patent applications, which will provide it with broad protection of its technology.

arGEN-X' SIMPLE Antibody(TM) Platform is
'/>"/>

SOURCE arGEN-X
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. arGEN-X SIMPLE Antibody(TM) Platform set to Transform Therapeutic Antibody Discovery & Development
2. arGEN-X Concludes EUR 12.5 Million Series A Financing Round
3. BSP Granted CE Mark for its HyperQ AD-100 Product Enabling Improved Diagnostic Performance of Stress ECG
4. Tolera Therapeutics Granted Orphan Drug Designation for Treatment of Type 1 diabetes mellitus
5. MultiCell Technologies Is Granted European Patent for the Treatment of Cancer
6. Solos Endoscopy, Inc. Granted U.S. Trademark for MammoView(R)
7. Acuo Technologies Announces Patent Granted for Asset Communication Format Within a Computer Network
8. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
9. SPO Medical Granted Innovative Baby Monitoring Patent
10. First iPierian Patent for Induced Pluripotent Stem Cell Technology Granted by United Kingdom Intellectual Property Office
11. FDA Determines VYVANSE(R) was Properly Granted Five-Year Market Exclusivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)...  Seres Health, a clinical-stage therapeutics company developing ... microbiome, announced today that Dr. David Cook ... Chief Scientific Officer, will be presenting at the ... (ICAAC). The presentation will highlight the scientific and ... bacterial spores derived from the human microbiome, and ...
(Date:8/28/2014)... PITTSBURGH , Aug. 28, 2014 /PRNewswire-iReach/ -- ... exhibiting at the 9 th Annual Global ... , September 8-9 th . The Global ... industry leaders in small molecule and biologic pharmaceutical ... address challenges that today,s manufacturers face, such as ...
(Date:8/28/2014)... Aug. 28, 2014 Reportlinker.com ... report is available in its catalogue: ... Asia-Pacific Markets to 2020 - Novel ... in Newly Diagnosed and Recurrent GBM ... Glioblastoma Multiforme Therapeutics ...
Breaking Medicine Technology:Seres Health to Present Clinical Findings at ICAAC 2014 Conference 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9
... WILMINGTON, Del., Oct. 26 Next Intelligence Corporation ( ... today announced the expansion of its channel program for ... and system integrators (SI) to explore the growing health ... members sales leads, education on technical and selling aspects ...
... (Nasdaq: GTIV ), the nation,s largest provider of ... present at the Oppenheimer 21st Annual Healthcare Conference in New ... and the Credit Suisse 2010 Healthcare Conference in Phoenix, AZ ... 10, 2010. The presentations will be available to ...
Cached Medicine Technology:Next Intelligence Health Expands US Channel Program 2Gentiva® Health Services to Present at the Oppenheimer and Credit Suisse Healthcare Conferences 2Gentiva® Health Services to Present at the Oppenheimer and Credit Suisse Healthcare Conferences 3
(Date:8/29/2014)... Aug. 29, 2014 (HealthDay News) -- The main ... the Middle East and North Africa originated in ... studied so-called community-acquired methicillin-resistant Staphylococcus aureus ... have not recently been hospitalized. These infections typically ... person-to-person contact or through touching contaminated objects such ...
(Date:8/29/2014)... August 29, 2014 For the fifth ... (Meso Foundation) will be observing September 26th as Mesothelioma ... Plaza, in New York. , Members of the ... RSVP . The Foundation will be providing t-shirts and ... years, mesothelioma community members have received attention from ...
(Date:8/29/2014)... 29, 2014 PreDiabetes Centers , the ... season by offering Web shoppers a 20% discount off orders ... the Company’s online healthy living shop, beginning September 1. ... priority when heading into the chilly fall season. , Autumn’s ... this season, people usually ditch the healthy salads and opt ...
(Date:8/29/2014)... August 29, 2014 Innovations Television, produced by ... upcoming episodes of Innovations, focusing on health and elderly care, ... show the number of Americans over 65 will nearly double ... to 20% in 2030, for a total of 72 million ... health, most have at least one chronic condition and use ...
(Date:8/29/2014)... Raleigh, NC (PRWEB) August 29, 2014 ... validated the idea that progression-free survival correlates with overall ... article on the new research. Click here to ... UK and The Netherlands studied the cases of 523 ... European chemotherapy studies. , “PFSR-18 [progression-free survival at ...
Breaking Medicine News(10 mins):Health News: European MRSA Originated in Sub-Saharan Africa, Study Finds 2Health News:Organization to Raise Awareness of Mesothelioma on the Today Show 2Health News:PreDiabetes Centers Online Store Launches Fall Savings Event 2Health News:Innovations with Ed Begley, Jr., Seeking Content for Upcoming Series on Health and Elder Care 2Health News:European Study Says Disease Progression Predicts Mesothelioma Survival Better Than Treatment Response, According to Surviving Mesothelioma 2
... Heart Failure Nurses in Boston, June ... 26-28, ... (AAHFN) 2008 Annual Meeting "Raising the Bar in Heart,Failure Care" is scheduled ... research and ways to,improve patient care. The compelling agenda and wonderful ...
... VYTEX(TM) NRL: THE NEW STANDARDIZED SOURCE MATERIAL FOR THE ... PRODUCTS ... Rapra Technology Limited has invited,Vystar Corporation to present its ... Dispersions Conference 2008 in Madrid in,January. "Vytex(TM) Natural ...
... patients with advanced kidney cancer whose options run out after ... , The study, presented today (Wednesday) at the European ... drug, axitinib, shrank tumours and delayed progression of the disease ... to treat. , In the study, scientists gave axitinib to ...
... Paramount Acquisition,Corp. (OTC Bulletin Board: PMQC, PMQCU, PMQCW) ... directors has established the close of,business on October 1, ... will be entitled to receive notice of and to ... held to consider and vote,on the previously announced acquisition ...
... Consider Proposals and Variations, LOS ANGELES, ... ISCR) a leading e-health Wi-Fi PDA technology ... DME and EMR applications,and the distributor of ... surgical products, announced today that its Board ...
... Spain: Using an ultrasound-guided fine needle to biopsy lymph ... worldwide from having to undergo unnecessary and sometimes unpleasant ... research indicates. , In a study presented today ... Barcelona, scientists found that the less invasive technique produced ...
Cached Medicine News:Health News:AAHFN's 2008 Annual Meeting in Boston Will Be 'Raising the Bar in Heart Failure Care' 2Health News:Global Latex Conference to Showcase Vytex(TM) NRL 2Health News:Experimental drug shows promise in advanced kidney cancer 2Health News:Paramount Acquisition Corp. Announces Record Date of October 1, 2007 for Proposed Acquisition of Chem Rx 2Health News:Paramount Acquisition Corp. Announces Record Date of October 1, 2007 for Proposed Acquisition of Chem Rx 3Health News:Paramount Acquisition Corp. Announces Record Date of October 1, 2007 for Proposed Acquisition of Chem Rx 4Health News:InstaCare Corp. Reviewing M&A Plans 2Health News:Less invasive lymph node biopsy method could spare thousands unnecessary operations 2
Cuffed pediatric endotracheal tubes, available from 2.5 mm to 4.5 mm inside diameter. Ruschelit® PVC. Magill tip - nasoral. X-ray opaque line. Graduated. Single use. Sterile...
Ruschelit® PVC. Murphy eye-nasoral. Black positioning ring. High volume/low pressure cuff. X-ray opaque line. Graduated. Single use....
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. Murphy eye. High volume/low pressure cuff. Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Steri...
... eye. Laser resistant foam surrounds the lower 17cm ... other) 40cm (16") long, Single Use. The tracheal ... optimum visibility within the operating site, while maintaining ... laser-guard of approx. 17cm in length proximal to ...
Medicine Products: